Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation

Bharathi Raja Rajaganapathy, Joseph J. Janicki, Peter Levanovich, Pradeep Tyagi, Jason Hafron, Michael B. Chancellor, Sarah Krueger, Brian Marples

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose We primarily determined whether the small animal radiation research platform could create a rat radiation cystitis model via targeted bladder irradiation (phase I). The response to treating early phase radiation cystitis in rats with transurethral catheter instillation of liposomal tacrolimus was also examined (phase II). Materials and Methods In phase I 16 adult female Sprague Dawley® rats were used. Metabolic urination patterns were analyzed before and after exposure to 20, 30 or 40 Gy radiation. In phase II irradiated rats were randomly assigned to receive a single instillation of saline or liposomal tacrolimus. Results The 40 Gy radiation dose induced statistically significant reductions in the intermicturition interval compared to the lower radiation doses. By approximately 20 minutes 40 Gy radiation caused a significant decrease in the mean intermicturition interval (p <0.0001). Histological analysis revealed degenerative epithelial changes and urothelial swelling with evidence of pseudocarcinomatous epithelial hyperplasia. Therefore, 40 Gy were chosen for the phase II efficacy study. There was no measurable change in total voided urine volume after irradiation, or after liposomal tacrolimus or saline instillation. Liposomal tacrolimus significantly increased the post-irradiation intermicturition interval by approximately 30 minutes back to baseline (p <0.001). Conclusions The radiation cystitis rat model showed a dose dependent decrease in the intermicturition interval without inducing short-term skin or gastrointestinal damage. This study demonstrates that liposomal tacrolimus may be a promising new intravesical therapy for the rare, serious condition of radiation cystitis.

Original languageEnglish (US)
Pages (from-to)578-584
Number of pages7
JournalJournal of Urology
Volume194
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Cystitis
Tacrolimus
Urinary Bladder
Radiation
Radiation Dosage
Urination
Hyperplasia
Sprague Dawley Rats
Catheters
Urine
Skin

Keywords

  • abnormalities
  • animal
  • cystitis
  • models
  • radiation-induced
  • tacrolimus
  • urinary bladder

ASJC Scopus subject areas

  • Urology

Cite this

Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. / Rajaganapathy, Bharathi Raja; Janicki, Joseph J.; Levanovich, Peter; Tyagi, Pradeep; Hafron, Jason; Chancellor, Michael B.; Krueger, Sarah; Marples, Brian.

In: Journal of Urology, Vol. 194, No. 2, 01.01.2015, p. 578-584.

Research output: Contribution to journalArticle

Rajaganapathy, BR, Janicki, JJ, Levanovich, P, Tyagi, P, Hafron, J, Chancellor, MB, Krueger, S & Marples, B 2015, 'Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation', Journal of Urology, vol. 194, no. 2, pp. 578-584. https://doi.org/10.1016/j.juro.2015.03.108
Rajaganapathy, Bharathi Raja ; Janicki, Joseph J. ; Levanovich, Peter ; Tyagi, Pradeep ; Hafron, Jason ; Chancellor, Michael B. ; Krueger, Sarah ; Marples, Brian. / Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. In: Journal of Urology. 2015 ; Vol. 194, No. 2. pp. 578-584.
@article{0e6dd0e902a745e8b1a305ed7b0db0ea,
title = "Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation",
abstract = "Purpose We primarily determined whether the small animal radiation research platform could create a rat radiation cystitis model via targeted bladder irradiation (phase I). The response to treating early phase radiation cystitis in rats with transurethral catheter instillation of liposomal tacrolimus was also examined (phase II). Materials and Methods In phase I 16 adult female Sprague Dawley{\circledR} rats were used. Metabolic urination patterns were analyzed before and after exposure to 20, 30 or 40 Gy radiation. In phase II irradiated rats were randomly assigned to receive a single instillation of saline or liposomal tacrolimus. Results The 40 Gy radiation dose induced statistically significant reductions in the intermicturition interval compared to the lower radiation doses. By approximately 20 minutes 40 Gy radiation caused a significant decrease in the mean intermicturition interval (p <0.0001). Histological analysis revealed degenerative epithelial changes and urothelial swelling with evidence of pseudocarcinomatous epithelial hyperplasia. Therefore, 40 Gy were chosen for the phase II efficacy study. There was no measurable change in total voided urine volume after irradiation, or after liposomal tacrolimus or saline instillation. Liposomal tacrolimus significantly increased the post-irradiation intermicturition interval by approximately 30 minutes back to baseline (p <0.001). Conclusions The radiation cystitis rat model showed a dose dependent decrease in the intermicturition interval without inducing short-term skin or gastrointestinal damage. This study demonstrates that liposomal tacrolimus may be a promising new intravesical therapy for the rare, serious condition of radiation cystitis.",
keywords = "abnormalities, animal, cystitis, models, radiation-induced, tacrolimus, urinary bladder",
author = "Rajaganapathy, {Bharathi Raja} and Janicki, {Joseph J.} and Peter Levanovich and Pradeep Tyagi and Jason Hafron and Chancellor, {Michael B.} and Sarah Krueger and Brian Marples",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.juro.2015.03.108",
language = "English (US)",
volume = "194",
pages = "578--584",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation

AU - Rajaganapathy, Bharathi Raja

AU - Janicki, Joseph J.

AU - Levanovich, Peter

AU - Tyagi, Pradeep

AU - Hafron, Jason

AU - Chancellor, Michael B.

AU - Krueger, Sarah

AU - Marples, Brian

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose We primarily determined whether the small animal radiation research platform could create a rat radiation cystitis model via targeted bladder irradiation (phase I). The response to treating early phase radiation cystitis in rats with transurethral catheter instillation of liposomal tacrolimus was also examined (phase II). Materials and Methods In phase I 16 adult female Sprague Dawley® rats were used. Metabolic urination patterns were analyzed before and after exposure to 20, 30 or 40 Gy radiation. In phase II irradiated rats were randomly assigned to receive a single instillation of saline or liposomal tacrolimus. Results The 40 Gy radiation dose induced statistically significant reductions in the intermicturition interval compared to the lower radiation doses. By approximately 20 minutes 40 Gy radiation caused a significant decrease in the mean intermicturition interval (p <0.0001). Histological analysis revealed degenerative epithelial changes and urothelial swelling with evidence of pseudocarcinomatous epithelial hyperplasia. Therefore, 40 Gy were chosen for the phase II efficacy study. There was no measurable change in total voided urine volume after irradiation, or after liposomal tacrolimus or saline instillation. Liposomal tacrolimus significantly increased the post-irradiation intermicturition interval by approximately 30 minutes back to baseline (p <0.001). Conclusions The radiation cystitis rat model showed a dose dependent decrease in the intermicturition interval without inducing short-term skin or gastrointestinal damage. This study demonstrates that liposomal tacrolimus may be a promising new intravesical therapy for the rare, serious condition of radiation cystitis.

AB - Purpose We primarily determined whether the small animal radiation research platform could create a rat radiation cystitis model via targeted bladder irradiation (phase I). The response to treating early phase radiation cystitis in rats with transurethral catheter instillation of liposomal tacrolimus was also examined (phase II). Materials and Methods In phase I 16 adult female Sprague Dawley® rats were used. Metabolic urination patterns were analyzed before and after exposure to 20, 30 or 40 Gy radiation. In phase II irradiated rats were randomly assigned to receive a single instillation of saline or liposomal tacrolimus. Results The 40 Gy radiation dose induced statistically significant reductions in the intermicturition interval compared to the lower radiation doses. By approximately 20 minutes 40 Gy radiation caused a significant decrease in the mean intermicturition interval (p <0.0001). Histological analysis revealed degenerative epithelial changes and urothelial swelling with evidence of pseudocarcinomatous epithelial hyperplasia. Therefore, 40 Gy were chosen for the phase II efficacy study. There was no measurable change in total voided urine volume after irradiation, or after liposomal tacrolimus or saline instillation. Liposomal tacrolimus significantly increased the post-irradiation intermicturition interval by approximately 30 minutes back to baseline (p <0.001). Conclusions The radiation cystitis rat model showed a dose dependent decrease in the intermicturition interval without inducing short-term skin or gastrointestinal damage. This study demonstrates that liposomal tacrolimus may be a promising new intravesical therapy for the rare, serious condition of radiation cystitis.

KW - abnormalities

KW - animal

KW - cystitis

KW - models

KW - radiation-induced

KW - tacrolimus

KW - urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=84983135324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983135324&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.03.108

DO - 10.1016/j.juro.2015.03.108

M3 - Article

C2 - 25839382

AN - SCOPUS:84983135324

VL - 194

SP - 578

EP - 584

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -